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Summary The expression of HLA class I antigens was studied in 99 primary tumours (colorectal, gastric and
laryngeal carcinomas) and 57 autologous metastases using immunohistological techniques and monoclonal
antibodies against class I monomorphic determinants, HLA-B isotypic determinants and HLA polymorphic
determinants. Fourteen per cent of colorectal, 9.6% of gastric and 20% of laryngeal carcinomas completely
lacked class I molecules. Selective losses of HLA-B antigens were also detected in 8.8, 3.4 and 5.8% of these
tumours respectively. Taking into account complete and selective loss of HLA-B the average alteration in the
class I molecules expression totalled 21%. The comparison ofclass I expression between primary tumours and
autologous metastases showed differences in 24% of the patients. These differences consisted mainly in a
decrease of class I expression by metastases. Nevertheless, four types of divergence were detected in laryngeal
carcinomas, namely: +/ -, +/ +, -/ +, -/-. In addition, a clear correlation between degree ofdifferentiation
and class I expression was observed in laryngeal tumours. Finally, when class I gene RFLPs were compared
with DNA from 15 tumours and autologous normal mucosa or peripheral lymphocytes, no differences were
detected between these samples.
Major histocompatibility antigens (H-2 in mice and HLA in
man) were discovered thanks to their role in alloimmune
interactions, generating alloantibodies and alloreactive CTLs
when transplants were performed between genetically differ-
ent individuals (Gorer et al., 1948). However, their physio-
logical function remains obscure. These antigens are
controlled by a cluster of genes located in chromosome 17 in
mice and chromosome 6 in humans. These genes code for
the classical transplantation antigens (class I), the immune
response associated antigens (class II) and complement genes
(class III) (Dausset, 1981). Class I antigens are cell surface
glycoproteins composed of a highly polymorphic heavy chain
(Mr 45,000) associated in a non-covalent way to fl2-micro-
globulin (Ploegh et al., 1981). Class I molecules are widely
distributed and expressed in most, but not all, nucleated cells
(Daar et al., 1984). Class II antigens are composed of two
glycosylated chains (Mr 32,000 and 29,000 respectively)
(Cullen et al., 1974), and are predominantly expressed by
cells involved in immunological phenomena (B cells, antigen
presenting cells and activated T lymphocytes) (Engleman et
al., 1980).
Histocompatibility class I and II antigens are involved in
different immunological and probably non-immunological
phenomena (Klein, 1986). Cytotoxic T-lymphocytes recog-
nise antigens in association with class I molecules
(Zinkernagel & Docherty, 1974), and natural killer cell
cytotoxicity has been shown to be inversely correlated with
the degree of class I expression (Kiirre, 1986). It is therefore
becoming evident that the immune response against modified
cells, virus infected cells or tumour cells is not only
influenced by the nature of the specific antigens but also by
the quantity and quality of class I molecules present at the
tumour cell surface (Fentestein & Schmidt, 1981, Garrido,
1988).
There is an increasing body of evidence which suggests
that MHC class I antigen expression is altered on mouse as
well as on human tumours (Fentestein & Garrido, 1986).
Two types of alterations have been described: (a) loss of
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class I antigens (Garrido et al., 1979; Schirrmacher et al.,
1981); and (b) expression of aberrant class I-like molecules
(Orgad et al., 1985; Garrido et al., 1976b; Phillips et al.,
1986). Furthermore, some reports indicate that these alter-
ations may play a crucial role in tumour dissemination and
metastasis (Eisenbach et al., 1985).
We present data which indicate that:
(a) complete loss of HLA expression may occur on colo-
rectal, gastric and laryngeal carcinomas;
(b) selective HLA-B losses occurred in three colorectal,
two laryngeal and one gastric carcinomas which were
previously considered class I positive;
(c) differing types of divergence of class I expression were
shown by primary tumours and autologous metastases;
(d) molecular genetic analysis of class I genes on several
tumours indicated no class I gene rearrangement or
gross depletion when compared to autologous DNA;
(e) finally, a strong correlation between the degree of
differentiation and class I expression was found in
laryngeal carcinomas.
Materials and methods
Tumour specimens
Tissue was obtained from patients under the case of the
Departments of General Surgery and Otorrhinolaryngology
(Virgen de las Nieves Hospital) who had not received
radiotherapy and/or chemotherapy before surgery. Histo-
pathological diagnosis was confirmed in paraffin sections.
All tissues were snap frozen in liquid nitrogen cooled
isopentane after coating with OCT within 1-2h of removal
and stored in liquid nitrogen until sectioning for study.
Cryostatic sections measuring 5-7,um thick were cut and
allowed to dry at room temperature for 14-18h, after which
they were fixed for 10min in acetone, wrapped in aluminium
foil and stored at -40°C until staining. A total of 99
primary tumours (34 colorectal, 31 gastric and 34 laryngeal
carcinomas) and 57 autologous metastases were studied.
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Monoclonal antibodies (MoAbs)
The following MoAbs were used: W6/32 against a common
class I determinant (A,B,C heavy chains) (Barnstable et al.,
1978); JOAN-1 (J. Vives) and ax-HLA-B (Burrone et al.,
1985) which recognise isotypic determinants in HLA mole-
cules; polymorphic MoAbs obtained from the Xth Histo-
compatibility Workshop (anti A2, numbers 2020, 2025, 2026
and 2027; anti All, numbers 2017 and 2045; anti B5,
number 2091; anti B14, number 2098; anti B44, number 2097
and anti Bw4, numbers 2102 and 2102); GRH1, against f2-
microglobulin, and GRT2, a MoAb which reacts against the
common leukocytic antigen (CD45), to measure lymphocytic
infiltration in tumours (Lopez-Nevot et al., 1986).
HLA typing
Peripheral blood lymphocytes were isolated by Ficoll-
Hypaque gradient centrifugation (Boyum, 1968) and HLA
typed by standard method microcytotoxicity (Terasaki &
McClelland, 1964). Tumour HLA typing was performed
by immunohistochemical techniques on cryostatic sections
(Cordell et al., 1984). The reaction obtained with the infil-
trating lymphocytes was used as a positive control in HLA-B
negative tumours.
Alkaline immunophosphatase technique
Tissue sections were incubated with the first antibody in a
moist chamber at room temperature for 45min. After wash-
ing with 0.05M Tris buffered saline (pH 7.6) (TBS), the
sections were incubated for 30min with rabbit antimouse
immunoglobulin at a dilution of 1:20 (DAKO), washed with
TBS and then reincubated for 30min with APAAP complex
at a dilution of 1:50 (DAKO). After washing with TBS,
fresh chromogen solution was added (0.2mgml-l naphthol
AS-MX phosphatase, 1 mgml-1 Fast Red salt, 20 1lml-
dimethylformamide, 0.05 M TRIS buffered saline pH 8.2)
(Sigma). A final washing with TBS was followed by counter-
staining with Haematoxylin and mounting with Apathy's
mounting solution (Cordell et al., 1984).
DNA isolation and Southern blot analysis
High molecular weight DNA was isolated from the tumours,
normal autologous mucosa and autologous peripheral blood
lymphocytes (Blin & Stafford, 1976). Aliquots 10pg of DNA
were digested with 150-300 units of different restriction
enzymes (EcoRi, HINDIII, BamHI, PstI, PvuII, MspI or
HpaII) for 4h according to the supplier's specifications
(Amersham). DNA fragments were separated by electro-
phoresis in 0.8% agarose gels for 16h and transferred to
nitrocellulose membranes (Southern, 1975). A 1.4Kbp
cDNA coding for HLA-B7 (pDP-001) was used as a probe
(Sood et al., 1981). Membranes were treated for hybridisa-
tion with nick-translated P32-labelled pDP-001 in 50%
formamide hybridisation solution for 36-40h at 42°C. Mem-
branes were washed at 65°C for 30min in two changes of
2 x SSC/O.1% SDS. After washing, the membranes were
dried, and autoradiographed at -70°C until the signals were
visible.
Results
Expression of class I antigens
Colorectal carcinomas We examined the expression of HLA
class I antigens on 34 colorectal primary tumours and 13
metastases (12 lymph node and one liver metastases).
Twenty-one primary tumours (61.8%) presented a homo-
geneous pattern of HLA-A, B and C antigen expression.
Five tumours also showed a positive but heterogeneous
pattern of expression, while five tumours were class I
negative (Table I). MoAbs were used against monomorphic
determinants of HLA-A, B and C and fl2-microglobulin.
There was no discrepancy among the reaction patterns
obtained with these MoAbs. However, differences were
observed in three patients (8.8%) when two HLA-B locus
specific MoAbs were used. These three patients showed
selective losses of HLA-B products.
Samples of normal mucosa from the same patients distal
or closer to the tumour were also studied. Benign lesions
(adenomas) were also included in the protocol. No alteration
in class I expression was observed in these samples. Nor was
any correlation found between the partial or complete loss of
class I antigen expression and the degree of differentiation of
the primary colorectal tumours studied (Table II).
The 13 colorectal metastases studied were class I positive.
Nevertheless, eight metastases presented a lower percentage
of positive cells than the autologous primary tumours (Table
III).
Gastric carcinomas Thirty-one primary gastric carcinomas
were studied. Class I antigens were completely absent in three
patients (9.6%) (Table I). Heterogeneous expression was
observed in five patients (16.1%) (between 25 and 75%
positive cells). Twenty-two patients (71.1%) showed positive
and heterogeneous class I expression. Selective loss of HLA-
B locus antigen was found in only one tumour.
HLA class I expression was considerable in 16/19 poorly
differentiated gastric carcinomas, whereas only 6/12 well
differentiated carcinomas were positive (Table II). Interest-
ingly, normal gastric mucosa showed weak, heterogeneous
HLA-A, B and C antigen expression. Thirty lymph node
metastases were studied, of which 27 were found to be class
I positive and three class I negative (Table III). Hence the
vast majority of lymph node metastases derived from gastric
tumours were class I positive.
Laryngeal carcinomas Thirty-four primary laryngeal carci-
nomas were studied, seven of which (20.5%) were class I
negative. In addition, B-locus losses were observed in two
tumours (5.8%) (Table I). The degree of differentiation was
Table I HLA class I antigen expression in colorectal, gastric and laryngeal carcinomas
Percentage reactivity with MoAbs against Number of tumours
A,B,C antigens/fl2-m HLA-B Colorectal Gastric Laryngeal
100 100 21 22 24
75-50 75-50 4 3 0
50-25 50-25 1 2 1
<25 <25 5b 3b 7b
100 <5 3a la 2a
Total number of primary tumours 34 31 34
aThree colorectal (8.8%), one gastric (3.4%) and two laryngeal tumours (5.8%) present
selective loss of HLA-B locus products. bIn 5/34 (14%) of colorectal, 3/29 (9.6%) of
stomach and 7/34 (20%) of laryngeal tumours HLA A, B and C antigens were completely
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Table II Relationship between class I expression on primary tumours and grade of differentiation
Colorectal (34)b Gastric (31) Laryngeal (34)
Class a I II III I II III I II III
100 8 10 3 1 5 16 8 16 -
75-25 1 2 2 - 3 2 - - 1
<25 1 3 1 1 1 1 1 - 6
HLA-B (-) - 3 - - 1 1 - 2 -
aPercentage of positive cells. bNumber of cases.
Degree of differentiation: I, well differentiated; II,
Table III Expression of class I antigens in lymph node
metastases of colorectal, gastric and laryngeal carcinomas
A,B,C antigens/f2-m HLA-B antigen
(+Itotal) (+/total)
Colorectal l3/13- 13/13
Gastric 27/30b 27/30
Laryngeal 9/14c 9/14
Total number of
metastases 57 57
'All 13 colorectal carcinoma metastases were HLA class I
positive. However, in eight cases class I expression was lower
than on autologous primary tumours. bThree gastric carci-
noma metastases were HLA class I negative. cFive laryngeal
carcinoma metastases were HLA class I negative.
strongly correlated with class I antigen expression. All
tumours expressing large amounts of HLA showed a well or
moderately differentiated pattern. On the contrary, 6/7 class
I negative tumours were poorly differentiated (Table II). It
was observed that normal laryngeal mucosa was always class
I positive, presenting a homogeneous staining pattern. Four-
teen autologous metastases were studied, of which nine were
found to be class I positive and five class I negative (Table
III).
Differences in HLA class I expression between primary
tumours and autologous metastases
The class I expression of 57 metastases was compared with
that of their autologous primary tumours. In most of the
patients there was no detectable difference. In eight patients
with colonic carcinoma and two with gastric carcinoma a
decrease in the number of HLA class I positive cells was
observed on the metastases (Table IV). In six laryngeal
carcinomas, four possible combinations of expression
between the primary tumour and its autologous metastases
(+/ +, +/-, -/+, -I-) were found (Table IV).
Selective loss of HLA-B locus products
Six of 99 primary tumours (6%) were found to be selective
for HLA-B antigen losses (Table I). Considering that the
amount of HLA class I losses reached 15% (15/99) we
believe that the 6% of B-locus losses should be added to this
figure, resulting in a total of 21%.
One case was selected from each tumour group to confirm
the HLA-B antigen loss. These three patients were HLA
typed using the standard Terasaki microcytotoxicity test on
PBLs. Tumour tissue was typed on frozen sections with
polymorphic HLA reagents using the immune alkaline phos-
phatase technique, in conjunction with MoAbs defining
polymorphic HLA determinants. These MoAbs were deve-
loped at the Xth International HLA workshop and define
the following specificities: A2, Al1, B5, B14, B21, B44 and
Bw4 (Table V).
The loss of B locus products in these tumours was
confirmed with polymorphic MoAbs. In all cases positive
reaction with the infiltrating lymphocytes was used as the
internal control. In one gastric tumour, HLA-A locus anti-
gens were also undetectable despite a positive reaction with
W6/32 and f2-microglobulin.
moderately differentiated; III, poorly differentiated.
Table IV Differences in HLA class I expression
antigen between primary tumour and autologous
lymph node metastasesa
Primary tumour Autologous metastases
LCI - -
LC2 - +MlC
+M2
LC3 + -Ml
-M2
LC5 + +
LC7 + -Ml
-M2
GClb +
GC2 + -
CClb + +
(-), Less than 25% of stained cells; (+), more than
25% of stained cells; LC, laryngeal carcinoma; GC,
gastric carcinoma; CC, colorectal carcinoma;
aFifty-seven metastases were studied. Most of the
patients showed no detectable differences when
class I antigen expression was compared between
primary tumour and autologous metastases. This
table illustrates several examples in which differ-
ences were found. bIn eight patients with colorectal
and two gastric carcinoma the number of positive
cells for class I antigens in the primary tumour was
higher than in metastases. cIn some patients it was
possible to compare HLA class I antigen expres-
sion among multiple metastases (Ml, M2) from the
same primary tumour.
Table V Selective loss of HLA class I antigen in human
tumours
Lymphocytic typing Tumour typing
Colon A2, -/B5, B21 A2, -/-,
Larynx A2, -/B5, B44 A2, -/-, -
Stomach A1, -/B14, B44 -, -/-, -
Lymphocytes were tested by standard method micro-
cytotoxicity and tumour typing by immunohistological
techniques using polymorphic monoclonal antibodies.
Comparative study of HLA class I genes from normal tissue
and autologous tumours
Southern blot analysis of class I genes was performed on 15
different tumours (10 colorectal, 2 gastric and 3 laryngeal
carcinomas). Normal autologous DNA extracted from
normal cells (autologous mucosa or PBL) was used as a
control, and pDP-001 was used as a probe. The 15 different
tumours selected included seven class I negative, three B-
locus negative and five class I positive specimens. No
differences were found in RFLPs of these tumours when
compared with normal autologous DNA (Figure 2). We also
included methylation sensitive enzymes, which failed to
detect differences between tumour and normal mucosa
DNA.224 M.A. LOPEZ-NEVOT et al.
a
b
Figure 1 Alkaline immunophosphatase stained cryostatic
sections of laryngeal carcinoma labelled with W6/32 (a) or anti-
HLA-B (b) monoclonal antibodies. (a) W6/32 reacting positively
on epithelial and stromal cells in a tumour section. (b) Anti-
HLA-B MoAb (JOAN-1) reacting negatively in the same
tumour. The stromal cells were stained in the same preparation
as a control.
Discussion
The phenotypic analysis of HLA class I molecules on
colorectal, gastric and laryngeal carcinomas with MoAbs
directed against monomorphic determinants reveals three
different reaction patterns: positive, heterogeneous and
negative.
Heterogeneity of class I expression has previously been
detected in breast carcinoma (Natali et al., 1983; Perez et al.,
1986) and in melanoma (Albino et al., 1981). The most
widely accepted explanation to date is based on the appear-
ance of clones with differential HLA class I expression in the
course of tumour progression (Ruiz-Cabello et al., 1987).
The loss of HLA class I expression is a relatively frequent
event in human neoplasias, and has been correlated with the
degree of differentiation in embryonic carcinoma (Lampson
et al., 1983), histological type in carcinoma of the lung
(Doyle et al., 1985), degree of tumour progression in mela-
noma (Brocker et al., 1985, Lopez-Nevot et al., 1986) and
also with the malignancy of B cell lymphomas (M6ller et al.,
1987).
Contrary to the findings described by others (Morburg et
al., 1986), no correlation between the loss of HLA class I
expression and the degree of cell differentiation was found in
colorectal carcinoma (Gutierrez et al., 1987). However, it
was noted that in laryngeal carcinomas most of the tumours
consisting of less differentiated cells were HLA class I
negative (6/7) whereas among moderately or well differen-
tiated carcinomas there was only one HLA class I negative
tumour. These data suggest that the loss of HLA class I
expression is closely related to the degree of cell differen-
c
Figure 2 Southern blot analysis of class I genes from colon (a),
gastric (b) and laryngeal (c) carcinoma. DNA from the tumour
(T) was compared with DNA from autologous normal mucosa
(M) or autologous lymphocytes (L). No differences in RFLPs
were observed. This probe was a cDNA of HLA-B7 (pDP001).
tiation in laryngeal carcinoma. This loss may also represent
an escape mechanism from cytotoxic T-cell mediated lysis, as
these cells recognise tumour antigens in association with
HLA class I molecules (Fentestein, 1987). On the other
hand, the loss of HLA class I expression may lead to
increased sensitivity of tumour cells to lysis by NK cells
(Ljungren et al., 1986). In gastric carcinoma, however, the
less differentiated cells are mainly HLA class I positive
exhibiting higher levels of expression than those observed in
normal gastric mucosa. This increased HLA class I expres-
sion may facilitate their metastatic progression by means of
diminishing their susceptibility to NK lysis.HLA CLASS I GENE EXPRESSION 225
When HLA class I expression on primary tumours was
compared with autologous metastases in laryngeal carci-
noma, some HLA class I positive primary tumours demon-
strated HLA class I negative metastases and vice versa.
These data suggest that several mechanisms of clonal selec-
tion may coexist during the course of tumour progression,
given the fact that there does not seem to be a simple
pattern of change in HLA class I expression. The differences
in HLA class I expression between primary tumours and
autologous metastases in colorectal and gastric carcinoma,
basically consisting of a decrease in the number of HLA
class I positive cells, were observed only in a small number
of cases.
Anti-HLA class I MoAb directed against a monomorphic
determinant does not effectively detect selective losses of
HLA-A, B or C antigen expression. However, when using
isotypic MoAbs directed against HLA-B specific deter-
minants it became possible to record losses of HLA-B
antigens in all three types of tumour studied. The reactivity
of the lymphoid infiltrate with these antibodies served as an
internal control. In these three tumours it was also possible
to confirm the absence of HLA-B molecules by means of
polymorphic MoAbs directed against the serologically
detected specificities found in autologous blood lymphocytes
by standard cytotoxicity assays. In one case of HLA class I
positive gastric carcinoma HLA-B reactivity was not
observed and anti-HLA-A MoAb assays were found to be
negative. As HLA-C antigens are generally expressed in
much lower amounts than HLA-A or B, the antibody W6/32
may, in this case, recognise HLA class I-like molecules which
are distinct from HLA-A, B or C.
These data speak in favour of the use of isotypic MoAbc
but also polymorphic antibodies in order more accurately tc
define alterations in HLA class I expression. Even with
isotypic MoAbs it would be difficult to detect a partial loss
of antigen expression if the defect was located in the
polymorphic domains of the molecule. Selective losses of
MHC class I antigens have been described in murine
tumours (Garrido et al., 1976b). These losses of K or D
molecules were correlated with an enhanced metastatic abi-
lity (Eisenbach et al., 1983). It has recently been reported
that the resistance of certain Burkitt lymphomas to lysis by
autologous cytotoxic T-lymphocytes may be due to the
selective loss of HLA-A11 antigen expression (Masucci et al.,
1988). Selective losses of HLA-B locus products have been
recently reported in colorectal carcinomas (Garrido, 1988;
Smith et al., 1988). The selective loss of HLA-B antigens
may give rise to a similar state. It would also be worthwhile
to study whether selective losses of HLA class I antigen
expression affect certain specificities more frequently than
others.
Southern blot analyses were performed to try to ascertain
whether the changes in HLA class I expression could be due
to a genomic structural alteration (rearrangement or gross
deletion) or perhaps to changes in the methylation pattern of
the CCGG base sequences (using the isoschizomeric pair of
restriction enzymes MspI and HpaII which are differentially
sensitive to methylation of the CCGG moiety). Data have
been obtained on the murine GR9 tumour which sub-
stantiate different class I methylation patterns between class
I positive and negative tumour clones (Bonal et al., 1986).
The loss of H-2 molecules in SV-40 and radiation leukaemia
virus induced tumours is associated with H-2 class I gene
rearrangement or CCGG hypermethylation (Rogers et al.,
1983, Meruelo et al., 1986). Loss of HLA class I gene
restriction fragments has been described in human melanoma
(Angelini et al., 1986) and colorectal carcinoma (Bar-Eli et
al., 1987). When tumour DNA was compared with that from
normal autologous cells it was not possible to detect clear
genomic alterations with the enzymes and probe (HLA class
I) used. In the present study HLA class I positive and
negative tumours as well as tumours with selective losses of
HLA-B locus products were investigated. The cause of
altered HLA class I expression in our tumours may therefore
be mediated by a transcriptional event. Selective losses of
HLA molecules without DNA damage suggest that the B-
locus can be regulated independently from the A-locus and
as similarly described on murine K and D class I molecules
(Gmur et al., 1980).
Further studies remain to be carried out in order to
analyse the alteration in histocompatibility antigens expres-
sion and its role in tumour progression and metastases.
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